Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia
- 30 April 2000
- journal article
- Published by Elsevier BV in Seminars in Hematology
- Vol. 37, 28-34
- https://doi.org/10.1016/s0037-1963(00)90050-7
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Recombinant Human Thrombopoietin Attenuates Carboplatin-Induced Severe Thrombocytopenia and the Need for Platelet Transfusions in Patients with Gynecologic CancerAnnals of Internal Medicine, 2000
- Enhanced retention of in vitro functional activity of platelets from recombinant human thrombopoietin‐treated patients following long‐term cryopreservation with a platelet‐preserving solution (ThromboSol) and 2% DMSOBritish Journal of Haematology, 1999
- The use of PEG‐rHuMGDF in platelet apheresisThe International Journal of Cell Cloning, 1998
- ERRATUMBlood, 1997
- Effects of Polyethylene Glycol–Conjugated Recombinant Human Megakaryocyte Growth and Development Factor on Platelet Counts after Chemotherapy for Lung CancerNew England Journal of Medicine, 1997
- Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor MpICell, 1994
- c-Mpl ligand is a humoral regulator of megakaryocytopoiesisNature, 1994
- Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivoNature, 1994
- Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligandNature, 1994